ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.
ACC 2019 The AUGUSTUS trial showed less bleeding and fewer hospitalizations without differences in ischemic events with apixaban and no aspirin, as compared with regimens with VKA, aspirin or both.
In a secondary analysis of the VISTA-16 trial, hsCRP levels measured at the time of ACS and increases of hsCRP in the 16 weeks after, were correlated with MACE, all-cause and CV death.
RETRACTION 7 Out of 13 studies included in a meta-analysis of RCTs on atorvastatin loading prior to PCI for ACS should have been excluded based on the study’s selection criteria. A corrected analysis substantively alters the results.
A retrospective analysis of RCTs suggests that when ischemic and bleeding risks are concordant, bleeding risk should inform decision-making on DAPT duration more so than ischemic risk.
Noise from road traffic, railway and aircraft were associated with MI mortality in a cohort of adults, independently of air pollution, in a model that assessed individual exposure at the address and floor level.
Self-reported consumption of ≥2 artificially sweetened beverages per day was associated with higher risk of CV events, and all-cause mortality in postmenopausal women, as shown in an observational study.
A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.
In a total events analysis of ODYSSEY OUTCOMES, treatment with alirocumab reduced the total burden of fatal and nonfatal CV events in a post-ACS population, as compared with placebo.
Obstructive CAD and adverse coronary plaque characteristics on CTA were associated with increased risk for CHD death or non-fatal MI, but CAC score was the only significant predictor of CHD risk in a post-hoc analysis of the SCOT-HEART trial.
A retrospective registry-based cohort study demonstrated that elevated cardiac troponin levels can predict major adverse outcomes in patients admitted with suspected ACS in whom no definite diagnosis was established.
A meta-analysis of 13 randomized controlled trials showed that a loading dose of atorvastatin before PCI markedly reduced MACE in patients with ACS.